Cargando…
P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429728/ http://dx.doi.org/10.1097/01.HS9.0000969384.56748.d2 |
| _version_ | 1785090783832965120 |
|---|---|
| author | Kater, Arnon Hodkinson, Brandon Moreno, Carol Munir, Talha Levin, Mark-David Niemann, Carsten Qi, Keqin Sinet, Pierre Baeten, Kurt Bennett Caces, Donne Srinivasan, Srimathi |
| author_facet | Kater, Arnon Hodkinson, Brandon Moreno, Carol Munir, Talha Levin, Mark-David Niemann, Carsten Qi, Keqin Sinet, Pierre Baeten, Kurt Bennett Caces, Donne Srinivasan, Srimathi |
| author_sort | Kater, Arnon |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429728 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104297282023-08-17 P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL Kater, Arnon Hodkinson, Brandon Moreno, Carol Munir, Talha Levin, Mark-David Niemann, Carsten Qi, Keqin Sinet, Pierre Baeten, Kurt Bennett Caces, Donne Srinivasan, Srimathi Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429728/ http://dx.doi.org/10.1097/01.HS9.0000969384.56748.d2 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Kater, Arnon Hodkinson, Brandon Moreno, Carol Munir, Talha Levin, Mark-David Niemann, Carsten Qi, Keqin Sinet, Pierre Baeten, Kurt Bennett Caces, Donne Srinivasan, Srimathi P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL |
| title | P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL |
| title_full | P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL |
| title_fullStr | P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL |
| title_full_unstemmed | P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL |
| title_short | P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL |
| title_sort | p620: genetic alterations and outcomes with fixed-duration ibrutinib+venetoclax (ibr+ven): results from the phase 3 glow study in patients with previously untreated cll |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429728/ http://dx.doi.org/10.1097/01.HS9.0000969384.56748.d2 |
| work_keys_str_mv | AT katerarnon p620geneticalterationsandoutcomeswithfixeddurationibrutinibvenetoclaxibrvenresultsfromthephase3glowstudyinpatientswithpreviouslyuntreatedcll AT hodkinsonbrandon p620geneticalterationsandoutcomeswithfixeddurationibrutinibvenetoclaxibrvenresultsfromthephase3glowstudyinpatientswithpreviouslyuntreatedcll AT morenocarol p620geneticalterationsandoutcomeswithfixeddurationibrutinibvenetoclaxibrvenresultsfromthephase3glowstudyinpatientswithpreviouslyuntreatedcll AT munirtalha p620geneticalterationsandoutcomeswithfixeddurationibrutinibvenetoclaxibrvenresultsfromthephase3glowstudyinpatientswithpreviouslyuntreatedcll AT levinmarkdavid p620geneticalterationsandoutcomeswithfixeddurationibrutinibvenetoclaxibrvenresultsfromthephase3glowstudyinpatientswithpreviouslyuntreatedcll AT niemanncarsten p620geneticalterationsandoutcomeswithfixeddurationibrutinibvenetoclaxibrvenresultsfromthephase3glowstudyinpatientswithpreviouslyuntreatedcll AT qikeqin p620geneticalterationsandoutcomeswithfixeddurationibrutinibvenetoclaxibrvenresultsfromthephase3glowstudyinpatientswithpreviouslyuntreatedcll AT sinetpierre p620geneticalterationsandoutcomeswithfixeddurationibrutinibvenetoclaxibrvenresultsfromthephase3glowstudyinpatientswithpreviouslyuntreatedcll AT baetenkurt p620geneticalterationsandoutcomeswithfixeddurationibrutinibvenetoclaxibrvenresultsfromthephase3glowstudyinpatientswithpreviouslyuntreatedcll AT bennettcacesdonne p620geneticalterationsandoutcomeswithfixeddurationibrutinibvenetoclaxibrvenresultsfromthephase3glowstudyinpatientswithpreviouslyuntreatedcll AT srinivasansrimathi p620geneticalterationsandoutcomeswithfixeddurationibrutinibvenetoclaxibrvenresultsfromthephase3glowstudyinpatientswithpreviouslyuntreatedcll |